Literature DB >> 18528681

[Use of bisphosphonates in orthopedic surgery].

R Bartl1, C Bartl, R Gradinger.   

Abstract

Over the past three decades, the members of the substance group called bisphosphonates (BP) have been employed with growing success to manage osteopathies caused by increased osteoclastic activity. The following developments in BP are responsible: Modern BP are now already 20,000 times more potent than the first preparation approved for use. Their biochemical and cellular mechanisms of action have meanwhile been elucidated. They have no effect on hormones so that they are open for all patients. They are well tolerated and can be administered orally or intravenously. They have admirably been thoroughly studied in multinational trials. They are the "gold standard" in the treatment of osteoporosis, a widespread disease. Rare but serious side effects such as osteonecrosis of the jaw or acute renal insufficiency can be avoided to a large extent. BP also have tumoricidal properties and are used to suppress tumor growth in bones. Their anti-inflammatory activity is also successfully used in the treatment of bone marrow edema and bone pain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18528681     DOI: 10.1007/s00132-008-1280-y

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.004


  24 in total

Review 1.  Aseptic loosening, not only a question of wear: a review of different theories.

Authors:  Mikael Sundfeldt; Lars V Carlsson; Carina B Johansson; Peter Thomsen; Christina Gretzer
Journal:  Acta Orthop       Date:  2006-04       Impact factor: 3.717

2.  Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.

Authors:  P Major; A Lortholary; J Hon; E Abdi; G Mills; H D Menssen; F Yunus; R Bell; J Body; E Quebe-Fehling; J Seaman
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

3.  Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

Authors:  Ian R Reid; Paul Miller; Kenneth Lyles; William Fraser; Jacques P Brown; Youssef Saidi; Peter Mesenbrink; Guoqin Su; Judy Pak; Ken Zelenakas; Monica Luchi; Peter Richardson; David Hosking
Journal:  N Engl J Med       Date:  2005-09-01       Impact factor: 91.245

4.  The Otto Aufranc Award: bone augmentation around and within porous implants by local bisphosphonate elution.

Authors:  Michael Tanzer; Dorota Karabasz; Jan J Krygier; Robert Cohen; J Dennis Bobyn
Journal:  Clin Orthop Relat Res       Date:  2005-12       Impact factor: 4.176

Review 5.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

6.  Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta.

Authors:  Y S Lee; S L Low; L A Lim; K Y Loke
Journal:  Eur J Pediatr       Date:  2001-11       Impact factor: 3.183

7.  Local peroperative treatment with a bisphosphonate improves the fixation of total knee prostheses: a randomized, double-blind radiostereometric study of 50 patients.

Authors:  Maria Hilding; Per Aspenberg
Journal:  Acta Orthop       Date:  2007-12       Impact factor: 3.717

8.  The effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty.

Authors:  Ching-Jen Wang; Jun-Wen Wang; Lin-Hsiu Weng; Chia-Chen Hsu; Chung-Cheng Huang; Han-Shiang Chen
Journal:  J Bone Joint Surg Am       Date:  2003-11       Impact factor: 5.284

Review 9.  Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.

Authors:  J J Body; R Bartl; P Burckhardt; P D Delmas; I J Diel; H Fleisch; J A Kanis; R A Kyle; G R Mundy; A H Paterson; R D Rubens
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

Review 10.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; N Burlet; C Cooper; P D Delmas; J-Y Reginster; F Borgstrom; R Rizzoli
Journal:  Osteoporos Int       Date:  2008-02-12       Impact factor: 4.507

View more
  5 in total

Review 1.  Bisphosphonates for advanced prostate cancer.

Authors:  Sascha Macherey; Ina Monsef; Franziska Jahn; Karin Jordan; Kwok Keung Yuen; Axel Heidenreich; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2017-12-26

2.  [Bone resorption in posttraumatic dystrophy. Root cause analysis based on the literature].

Authors:  A Scola; E Scola
Journal:  Unfallchirurg       Date:  2014-10       Impact factor: 1.000

Review 3.  Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.

Authors:  Yundong He; Weidong Xu; Yu-Tian Xiao; Haojie Huang; Di Gu; Shancheng Ren
Journal:  Signal Transduct Target Ther       Date:  2022-06-24

4.  The effect of vitamin D and bisphosphonate on fracture healing: An experimental study.

Authors:  Nevres Hürriyet Aydoğan; İrfan Özel; Serkan İltar; Talip Kara; Ahmet Özmeriç; Kadir Bahadır Alemdaroğlu
Journal:  J Clin Orthop Trauma       Date:  2016-02-04

5.  Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.

Authors:  Tina Jakob; Yonas Mehari Tesfamariam; Sascha Macherey; Kathrin Kuhr; Anne Adams; Ina Monsef; Axel Heidenreich; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-12-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.